These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 20385853)
1. Intravenous voriconazole after toxic oral administration. Alffenaar JW; van Assen S; de Monchy JG; Uges DR; Kosterink JG; van der Werf TS Antimicrob Agents Chemother; 2010 Jun; 54(6):2741-2. PubMed ID: 20385853 [TBL] [Abstract][Full Text] [Related]
2. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction. Spriet I; Grootaert V; Meyfroidt G; Debaveye Y; Willems L Eur J Clin Pharmacol; 2013 Mar; 69(3):737-8. PubMed ID: 22878691 [No Abstract] [Full Text] [Related]
3. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632 [TBL] [Abstract][Full Text] [Related]
4. Two cases of cerebral aspergillosis successfully treated with voriconazole. de Lastours V; Lefort A; Zappa M; Dufour V; Belmatoug N; Fantin B Eur J Clin Microbiol Infect Dis; 2003 May; 22(5):297-9. PubMed ID: 12740666 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis. Hafner V; Albermann N; Haefeli WE; Ebinger F Antimicrob Agents Chemother; 2008 Nov; 52(11):4172-4. PubMed ID: 18794387 [TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. Levin MD; den Hollander JG; van der Holt B; Rijnders BJ; van Vliet M; Sonneveld P; van Schaik RH J Antimicrob Chemother; 2007 Nov; 60(5):1104-7. PubMed ID: 17827141 [TBL] [Abstract][Full Text] [Related]
7. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709 [TBL] [Abstract][Full Text] [Related]
8. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens. Burhenne J; Haefeli WE; Hess M; Scope A J Avian Med Surg; 2008 Sep; 22(3):199-207. PubMed ID: 19014092 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. Peng LW; Lien YH Am J Kidney Dis; 2005 Jan; 45(1):162-6. PubMed ID: 15696456 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses. Clode AB; Davis JL; Salmon J; Michau TM; Gilger BC Am J Vet Res; 2006 Feb; 67(2):296-301. PubMed ID: 16454636 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931 [TBL] [Abstract][Full Text] [Related]
13. Pseudoporphyria as a result of voriconazole use: a case report. Dolan CK; Hall MA; Blazes DL; Norwood CW Int J Dermatol; 2004 Oct; 43(10):768-71. PubMed ID: 15485539 [TBL] [Abstract][Full Text] [Related]
14. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685 [TBL] [Abstract][Full Text] [Related]
16. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Shima H; Miharu M; Osumi T; Takahashi T; Shimada H Pediatr Blood Cancer; 2010 Jul; 54(7):1050-2. PubMed ID: 20146339 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas. Chan HM; Duran SH; Walz PH; Ravis WR J Vet Pharmacol Ther; 2009 Jun; 32(3):235-40. PubMed ID: 19646087 [TBL] [Abstract][Full Text] [Related]
18. Adverse reactions to voriconazole. Boyd AE; Modi S; Howard SJ; Moore CB; Keevil BG; Denning DW Clin Infect Dis; 2004 Oct; 39(8):1241-4. PubMed ID: 15486850 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan Amazon parrots (Amazona ventralis). Sanchez-Migallon Guzman D; Flammer K; Papich MG; Grooters AM; Shaw S; Applegate J; Tully TN Am J Vet Res; 2010 Apr; 71(4):460-7. PubMed ID: 20367055 [TBL] [Abstract][Full Text] [Related]
20. [Case of Scedosporium apiospermum cutaneous soft tissue infection treated with voriconazole]. Konishi M; Yonekawa S; Nakagawa C; Uno K; Kasahara K; Yoshimoto E; Maeda K; Mikasa K Kansenshogaku Zasshi; 2008 Mar; 82(2):82-5. PubMed ID: 18411765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]